{"gene":"GDI2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2024,"finding":"Itaconate directly alkylates GDI2 at cysteines 203, 335, and 414, impairing GDI2's ability to extract Rab GTPases from the membrane to the cytoplasm, thereby retaining Rab GTPases on the membrane and facilitating viral infection. This effect requires prior geranylgeranylation of Rab GTPases by GGTase-II.","method":"Activity-based alkylation assay, site-directed mutagenesis of GDI2 cysteine residues, co-culture and in vivo animal experiments, single-cell RNA sequencing","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct biochemical alkylation with identified residues, mutagenesis validation, in vivo confirmation, multiple orthogonal methods","pmids":["39730330"],"is_preprint":false},{"year":2023,"finding":"GDI2 interacts with Rab1A, and disruption of this interaction (by compound BQZ-485 binding at Tyr245) abolishes ER-to-Golgi vesicular transport, triggering ER dilation, ER stress, unfolded protein response, and paraptotic cell death.","method":"Activity-based protein profiling, NanoLuc-based screening, Co-IP/pulldown (GDI2-Rab1A interaction), pharmacological inhibition and targeted degradation, in vivo xenograft models","journal":"JACS Au","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — activity-based protein profiling identified the target, interaction with Rab1A confirmed, functional consequence of disruption validated in vitro and in vivo with multiple orthogonal methods","pmids":["37885576"],"is_preprint":false},{"year":2024,"finding":"GDI2 knockout in neurons of 5xFAD mice led to increased APP co-localization with the ER rather than the Golgi apparatus and endosomes in SH-SY5Y cells, resulting in decreased Aβ production, indicating GDI2 regulates APP intracellular transport and processing.","method":"Neuron-specific GDI2 knockout in 5xFAD mice, immunofluorescence co-localization of APP with ER/Golgi/endosome markers, Aβ quantification, cognitive behavioral testing","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean neuron-specific KO with defined cellular phenotype and localization data, single lab, two orthogonal methods","pmids":["38382624"],"is_preprint":false},{"year":2022,"finding":"Complete loss of Gdi2 in mice results in early embryonic lethality with developmental retardation apparent at E10.5–E14.5, extensive cell death confirmed by cleaved caspase-3 staining, indicating GDI2 is essential for embryonic development and cell survival via the caspase apoptosis pathway.","method":"Gdi2 null mutant mouse generation, X-gal and immunohistochemistry staining, TUNEL staining, cleaved caspase-3 immunostaining","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined developmental and apoptotic phenotype, multiple histological methods, single lab","pmids":["35689892"],"is_preprint":false},{"year":2024,"finding":"GDI2 protein physically interacts with RAB5A (confirmed by co-immunoprecipitation); silencing GDI2 increases RAB5A availability, which activates the p53 signaling pathway (increased p-p53 and p-p21), causing G0/G1 cell cycle arrest and reducing proliferation, migration, and invasion of colorectal cancer cells. Overexpression of RAB5A or addition of p53 inhibitor Pifithrin-α reversed these effects.","method":"Co-immunoprecipitation of GDI2 and RAB5A, shRNA-mediated GDI2 silencing, flow cytometry cell cycle analysis, transcriptomic analysis, Western blot, xenograft tumor model, epistasis rescue experiments","journal":"Heliyon","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP confirmed interaction, epistasis rescue with overexpression and pharmacological inhibitor, single lab with multiple orthogonal methods","pmids":["39323841"],"is_preprint":false},{"year":2021,"finding":"GDI2 knockdown in prostate cancer cells suppresses proliferation and promotes apoptosis; knockdown activates the p75NTR signaling pathway, establishing a negative correlation between GDI2 expression and p75NTR activity. Paclitaxel treatment reduces GDI2 expression.","method":"shRNA-mediated GDI2 knockdown, CCK8 proliferation assay, apoptosis assay, qRT-PCR and Western blot for p75NTR and p-NFκB, nude mouse xenograft model","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — KD with phenotype and pathway association, but mechanistic link between GDI2 and p75NTR is not biochemically established, single lab, single method per endpoint","pmids":["34051575"],"is_preprint":false},{"year":2007,"finding":"Mass spectrometry identified post-translational modifications on GDI2 following spinal cord injury in rats: 3-aminotyrosine formation (8 h post-injury, indicating protein nitration) and an acrolein adduct (72 h post-injury, indicating lipid peroxidation-derived modification).","method":"Mass spectrometry identification of modified GDI2 peptides from spinal cord injury rat model","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — mass spectrometry unambiguously identified PTMs on GDI2, but single study with no functional follow-up on the modifications","pmids":["17315910"],"is_preprint":false},{"year":2020,"finding":"GDI2 is a direct transcriptional target of miR-15b-5p; dual-luciferase assay confirmed miR-15b-5p binds GDI2 mRNA. miR-15b-5p-mediated suppression of GDI2 reduces MMP2 and MMP9 expression and inhibits thyroid carcinoma cell invasion and proliferation; GDI2 overexpression rescues these effects.","method":"Dual-luciferase reporter assay, miRNA overexpression/inhibition, Western blot, CCK-8, Transwell invasion assay, rescue experiments with GDI2 overexpression","journal":"Molecular medicine reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — direct miRNA-target interaction confirmed by luciferase assay, but downstream mechanistic pathway (GDI2 to MMP2/9) not biochemically resolved, single lab","pmids":["32945458"],"is_preprint":false}],"current_model":"GDI2 (Rab GDP dissociation inhibitor beta) functions as a cytosolic regulator that extracts GDP-bound Rab GTPases from membranes and maintains them in inactive cytoplasmic complexes; it interacts directly with Rab proteins (including Rab1A and Rab5A), controls ER-to-Golgi vesicular transport and APP intracellular trafficking, is essential for embryonic development (complete KO causes caspase-mediated embryonic lethality), and can be inactivated by itaconate-mediated alkylation at Cys203/335/414 or by small-molecule inhibitors targeting Tyr245, disrupting Rab cycling and downstream vesicular transport pathways."},"narrative":{"mechanistic_narrative":"GDI2 is a cytosolic regulator of the Rab GTPase cycle that extracts GDP-bound, geranylgeranylated Rab GTPases from membranes to maintain them in inactive cytoplasmic pools, thereby governing membrane trafficking [PMID:39730330]. It binds Rab1A directly, and disrupting this interaction collapses ER-to-Golgi vesicular transport, producing ER dilation, ER stress, the unfolded protein response, and paraptotic cell death [PMID:37885576]. GDI2 activity is chemically tunable: itaconate alkylates cysteines 203, 335, and 414 to block Rab extraction and retain Rabs on membranes [PMID:39730330], and the small molecule BQZ-485 engages Tyr245 to abolish the GDI2–Rab1A interaction [PMID:37885576]. Through control of Rab-dependent trafficking, GDI2 directs the intracellular routing of amyloid precursor protein, with neuronal GDI2 loss shifting APP toward the ER and away from the Golgi and endosomes to lower Aβ production [PMID:38382624]. GDI2 also physically interacts with RAB5A, and its loss elevates free RAB5A to engage p53–p21 signaling and impose G0/G1 arrest [PMID:39323841]. Complete loss of Gdi2 in mice causes early embryonic lethality with widespread caspase-3–dependent cell death, establishing the gene as essential for development and cell survival [PMID:35689892].","teleology":[{"year":2007,"claim":"Establishing that GDI2 is subject to oxidative/nitrative post-translational modification under tissue stress raised the question of whether such modifications alter its trafficking function.","evidence":"Mass spectrometry of modified GDI2 peptides from a rat spinal cord injury model","pmids":["17315910"],"confidence":"Medium","gaps":["No functional consequence of the 3-aminotyrosine or acrolein modifications was tested","Modified residues not linked to Rab-binding or extraction activity"]},{"year":2020,"claim":"Identifying GDI2 as a direct miR-15b-5p target connected its expression level to tumor cell invasion, but left the downstream effector route unresolved.","evidence":"Dual-luciferase reporter assay with miRNA over/under-expression and GDI2 rescue in thyroid carcinoma cells","pmids":["32945458"],"confidence":"Low","gaps":["Biochemical link from GDI2 to MMP2/MMP9 not established","No connection to the Rab-extraction mechanism","Single lab, single cancer context"]},{"year":2021,"claim":"GDI2 knockdown phenotypes in prostate cancer associated the protein with proliferation and apoptosis control via p75NTR, framing it as a candidate cancer dependency.","evidence":"shRNA knockdown with proliferation/apoptosis assays and p75NTR/NF-κB readouts plus xenograft","pmids":["34051575"],"confidence":"Low","gaps":["Mechanistic link between GDI2 and p75NTR not biochemically established","Single method per endpoint","No connection to Rab cycling demonstrated"]},{"year":2022,"claim":"Defining the consequence of total GDI2 loss in vivo answered whether the gene is essential, showing it is required for embryonic survival.","evidence":"Gdi2 null mouse with histology, TUNEL, and cleaved caspase-3 staining","pmids":["35689892"],"confidence":"Medium","gaps":["Which Rab-dependent trafficking step underlies the lethality is not defined","Cell-type origin of the apoptotic phenotype not pinpointed","No rescue experiment"]},{"year":2023,"claim":"Pinpointing a direct GDI2–Rab1A interaction and a druggable Tyr245 site mechanistically tied GDI2 to ER-to-Golgi transport and to ER-stress-driven cell death.","evidence":"Activity-based protein profiling, NanoLuc screening, Co-IP/pulldown, BQZ-485 pharmacology and xenograft","pmids":["37885576"],"confidence":"High","gaps":["Whether Rab1A is the sole client mediating the paraptotic phenotype is unresolved","Structural basis of the Tyr245-dependent interaction not solved"]},{"year":2024,"claim":"Identifying itaconate alkylation at Cys203/335/414 defined a physiological switch that inhibits GDI2-mediated Rab extraction, linking metabolite signaling to membrane Rab retention and viral infection.","evidence":"Activity-based alkylation assay, cysteine-mutant validation, GGTase-II dependence, in vivo and single-cell RNA-seq","pmids":["39730330"],"confidence":"High","gaps":["Which specific Rab clients are most affected by alkylation in vivo not fully enumerated","Quantitative impact on distinct trafficking routes not resolved"]},{"year":2024,"claim":"Connecting GDI2 to APP routing and to RAB5A/p53 signaling extended its trafficking role into disease-relevant outputs (Aβ production and cell-cycle control).","evidence":"Neuron-specific Gdi2 KO in 5xFAD mice with APP co-localization and Aβ assays; reciprocal Co-IP of GDI2-RAB5A with epistasis rescue in colorectal cancer cells","pmids":["38382624","39323841"],"confidence":"Medium","gaps":["Whether APP rerouting is a direct Rab effect or indirect not dissected","How GDI2 loss increases free RAB5A to activate p53 mechanistically unresolved","Cross-tissue generality not tested"]},{"year":null,"claim":"The full spectrum of GDI2 Rab clients and how client selectivity dictates distinct trafficking and disease outcomes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No comprehensive map of GDI2-extracted Rabs across cell types","Structural model of GDI2-Rab membrane extraction not established in this corpus","Causal Mendelian disease link absent from the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,4]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[1,2]}],"complexes":[],"partners":["RAB1A","RAB5A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50395","full_name":"Rab GDP dissociation inhibitor beta","aliases":["Guanosine diphosphate dissociation inhibitor 2","GDI-2"],"length_aa":445,"mass_kda":50.7,"function":"GDP-dissociation inhibitor preventing the GDP to GTP exchange of most Rab proteins. By keeping these small GTPases in their inactive GDP-bound form regulates intracellular membrane trafficking (PubMed:25860027). Negatively regulates protein transport to the cilium and ciliogenesis through the inhibition of RAB8A (PubMed:25860027)","subcellular_location":"Cytoplasm; Membrane; Golgi apparatus, trans-Golgi network","url":"https://www.uniprot.org/uniprotkb/P50395/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GDI2","classification":"Not Classified","n_dependent_lines":83,"n_total_lines":1208,"dependency_fraction":0.06870860927152318},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000057608","cell_line_id":"CID000360","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"vesicles","grade":2},{"compartment":"nucleoplasm","grade":1}],"interactors":[{"gene":"RAB13","stoichiometry":10.0},{"gene":"RAB5C","stoichiometry":10.0},{"gene":"RAB4A","stoichiometry":10.0},{"gene":"HSPA1B;HSPA1A","stoichiometry":10.0},{"gene":"RAB35","stoichiometry":10.0},{"gene":"RAB14","stoichiometry":10.0},{"gene":"RAB11A","stoichiometry":10.0},{"gene":"RAB5A","stoichiometry":4.0},{"gene":"RAB1B","stoichiometry":4.0},{"gene":"RAB10","stoichiometry":4.0}],"url":"https://opencell.sf.czbiohub.org/target/CID000360","total_profiled":1310},"omim":[{"mim_id":"621535","title":"SPINOCEREBELLAR ATAXIA 52; SCA52","url":"https://www.omim.org/entry/621535"},{"mim_id":"620175","title":"RUBICON-LIKE AUTOPHAGY ENHANCER; RUBCNL","url":"https://www.omim.org/entry/620175"},{"mim_id":"604204","title":"SYNTAXIN 17; STX17","url":"https://www.omim.org/entry/604204"},{"mim_id":"600767","title":"GDP-DISSOCIATION INHIBITOR 2; GDI2","url":"https://www.omim.org/entry/600767"},{"mim_id":"300104","title":"GDP DISSOCIATION INHIBITOR 1; GDI1","url":"https://www.omim.org/entry/300104"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GDI2"},"hgnc":{"alias_symbol":["RABGDIB"],"prev_symbol":[]},"alphafold":{"accession":"P50395","domains":[{"cath_id":"3.50.50.60","chopping":"3-41_231-291_387-441","consensus_level":"medium","plddt":92.0957,"start":3,"end":441},{"cath_id":"3.30.519.10","chopping":"57-105_295-385","consensus_level":"medium","plddt":96.4087,"start":57,"end":385},{"cath_id":"1.10.405.10","chopping":"119-217","consensus_level":"high","plddt":94.5549,"start":119,"end":217}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50395","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50395-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50395-F1-predicted_aligned_error_v6.png","plddt_mean":93.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GDI2","jax_strain_url":"https://www.jax.org/strain/search?query=GDI2"},"sequence":{"accession":"P50395","fasta_url":"https://rest.uniprot.org/uniprotkb/P50395.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50395/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50395"}},"corpus_meta":[{"pmid":"34051575","id":"PMC_34051575","title":"GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34051575","citation_count":17,"is_preprint":false},{"pmid":"39730330","id":"PMC_39730330","title":"Itaconate facilitates viral infection via alkylating GDI2 and retaining Rab GTPase on the membrane.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39730330","citation_count":16,"is_preprint":false},{"pmid":"17315910","id":"PMC_17315910","title":"Nitric oxide and oxygen radical attack on GDP-dissociation inhibitor 2 (GDI-2) in spinal cord injury of the rat.","date":"2007","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/17315910","citation_count":14,"is_preprint":false},{"pmid":"32945458","id":"PMC_32945458","title":"MicroRNA‑15b‑5p exerts its tumor repressive role via targeting GDI2: A novel insight into the pathogenesis of thyroid carcinoma.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32945458","citation_count":10,"is_preprint":false},{"pmid":"37885576","id":"PMC_37885576","title":"Targeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[a]quinolizidine Library to Induce Paraptosis for Cancer Therapy.","date":"2023","source":"JACS Au","url":"https://pubmed.ncbi.nlm.nih.gov/37885576","citation_count":5,"is_preprint":false},{"pmid":"35689892","id":"PMC_35689892","title":"Targeted disruption of Gdi2 causes early embryonic lethality.","date":"2022","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/35689892","citation_count":4,"is_preprint":false},{"pmid":"39831280","id":"PMC_39831280","title":"The Novel Role of GDI2: A Mini-Review.","date":"2024","source":"Annals of medicine and medical research","url":"https://pubmed.ncbi.nlm.nih.gov/39831280","citation_count":1,"is_preprint":false},{"pmid":"39323841","id":"PMC_39323841","title":"Silencing GDI2 inhibits proliferation, migration and invasion of colorectal cancer through activation of p53 signaling pathway.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39323841","citation_count":1,"is_preprint":false},{"pmid":"38382624","id":"PMC_38382624","title":"GDI2 deletion alleviates neurodegeneration and memory loss in the 5xFAD mice model of Alzheimer's disease.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38382624","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":7039,"output_tokens":2215,"usd":0.027171,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9211,"output_tokens":2627,"usd":0.055865,"stage2_stop_reason":"end_turn"},"total_usd":0.083036,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2024,\n      \"finding\": \"Itaconate directly alkylates GDI2 at cysteines 203, 335, and 414, impairing GDI2's ability to extract Rab GTPases from the membrane to the cytoplasm, thereby retaining Rab GTPases on the membrane and facilitating viral infection. This effect requires prior geranylgeranylation of Rab GTPases by GGTase-II.\",\n      \"method\": \"Activity-based alkylation assay, site-directed mutagenesis of GDI2 cysteine residues, co-culture and in vivo animal experiments, single-cell RNA sequencing\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct biochemical alkylation with identified residues, mutagenesis validation, in vivo confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"39730330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GDI2 interacts with Rab1A, and disruption of this interaction (by compound BQZ-485 binding at Tyr245) abolishes ER-to-Golgi vesicular transport, triggering ER dilation, ER stress, unfolded protein response, and paraptotic cell death.\",\n      \"method\": \"Activity-based protein profiling, NanoLuc-based screening, Co-IP/pulldown (GDI2-Rab1A interaction), pharmacological inhibition and targeted degradation, in vivo xenograft models\",\n      \"journal\": \"JACS Au\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — activity-based protein profiling identified the target, interaction with Rab1A confirmed, functional consequence of disruption validated in vitro and in vivo with multiple orthogonal methods\",\n      \"pmids\": [\"37885576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GDI2 knockout in neurons of 5xFAD mice led to increased APP co-localization with the ER rather than the Golgi apparatus and endosomes in SH-SY5Y cells, resulting in decreased Aβ production, indicating GDI2 regulates APP intracellular transport and processing.\",\n      \"method\": \"Neuron-specific GDI2 knockout in 5xFAD mice, immunofluorescence co-localization of APP with ER/Golgi/endosome markers, Aβ quantification, cognitive behavioral testing\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean neuron-specific KO with defined cellular phenotype and localization data, single lab, two orthogonal methods\",\n      \"pmids\": [\"38382624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Complete loss of Gdi2 in mice results in early embryonic lethality with developmental retardation apparent at E10.5–E14.5, extensive cell death confirmed by cleaved caspase-3 staining, indicating GDI2 is essential for embryonic development and cell survival via the caspase apoptosis pathway.\",\n      \"method\": \"Gdi2 null mutant mouse generation, X-gal and immunohistochemistry staining, TUNEL staining, cleaved caspase-3 immunostaining\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined developmental and apoptotic phenotype, multiple histological methods, single lab\",\n      \"pmids\": [\"35689892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GDI2 protein physically interacts with RAB5A (confirmed by co-immunoprecipitation); silencing GDI2 increases RAB5A availability, which activates the p53 signaling pathway (increased p-p53 and p-p21), causing G0/G1 cell cycle arrest and reducing proliferation, migration, and invasion of colorectal cancer cells. Overexpression of RAB5A or addition of p53 inhibitor Pifithrin-α reversed these effects.\",\n      \"method\": \"Co-immunoprecipitation of GDI2 and RAB5A, shRNA-mediated GDI2 silencing, flow cytometry cell cycle analysis, transcriptomic analysis, Western blot, xenograft tumor model, epistasis rescue experiments\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP confirmed interaction, epistasis rescue with overexpression and pharmacological inhibitor, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39323841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDI2 knockdown in prostate cancer cells suppresses proliferation and promotes apoptosis; knockdown activates the p75NTR signaling pathway, establishing a negative correlation between GDI2 expression and p75NTR activity. Paclitaxel treatment reduces GDI2 expression.\",\n      \"method\": \"shRNA-mediated GDI2 knockdown, CCK8 proliferation assay, apoptosis assay, qRT-PCR and Western blot for p75NTR and p-NFκB, nude mouse xenograft model\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — KD with phenotype and pathway association, but mechanistic link between GDI2 and p75NTR is not biochemically established, single lab, single method per endpoint\",\n      \"pmids\": [\"34051575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mass spectrometry identified post-translational modifications on GDI2 following spinal cord injury in rats: 3-aminotyrosine formation (8 h post-injury, indicating protein nitration) and an acrolein adduct (72 h post-injury, indicating lipid peroxidation-derived modification).\",\n      \"method\": \"Mass spectrometry identification of modified GDI2 peptides from spinal cord injury rat model\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — mass spectrometry unambiguously identified PTMs on GDI2, but single study with no functional follow-up on the modifications\",\n      \"pmids\": [\"17315910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDI2 is a direct transcriptional target of miR-15b-5p; dual-luciferase assay confirmed miR-15b-5p binds GDI2 mRNA. miR-15b-5p-mediated suppression of GDI2 reduces MMP2 and MMP9 expression and inhibits thyroid carcinoma cell invasion and proliferation; GDI2 overexpression rescues these effects.\",\n      \"method\": \"Dual-luciferase reporter assay, miRNA overexpression/inhibition, Western blot, CCK-8, Transwell invasion assay, rescue experiments with GDI2 overexpression\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — direct miRNA-target interaction confirmed by luciferase assay, but downstream mechanistic pathway (GDI2 to MMP2/9) not biochemically resolved, single lab\",\n      \"pmids\": [\"32945458\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GDI2 (Rab GDP dissociation inhibitor beta) functions as a cytosolic regulator that extracts GDP-bound Rab GTPases from membranes and maintains them in inactive cytoplasmic complexes; it interacts directly with Rab proteins (including Rab1A and Rab5A), controls ER-to-Golgi vesicular transport and APP intracellular trafficking, is essential for embryonic development (complete KO causes caspase-mediated embryonic lethality), and can be inactivated by itaconate-mediated alkylation at Cys203/335/414 or by small-molecule inhibitors targeting Tyr245, disrupting Rab cycling and downstream vesicular transport pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GDI2 is a cytosolic regulator of the Rab GTPase cycle that extracts GDP-bound, geranylgeranylated Rab GTPases from membranes to maintain them in inactive cytoplasmic pools, thereby governing membrane trafficking [#0]. It binds Rab1A directly, and disrupting this interaction collapses ER-to-Golgi vesicular transport, producing ER dilation, ER stress, the unfolded protein response, and paraptotic cell death [#1]. GDI2 activity is chemically tunable: itaconate alkylates cysteines 203, 335, and 414 to block Rab extraction and retain Rabs on membranes [#0], and the small molecule BQZ-485 engages Tyr245 to abolish the GDI2–Rab1A interaction [#1]. Through control of Rab-dependent trafficking, GDI2 directs the intracellular routing of amyloid precursor protein, with neuronal GDI2 loss shifting APP toward the ER and away from the Golgi and endosomes to lower Aβ production [#2]. GDI2 also physically interacts with RAB5A, and its loss elevates free RAB5A to engage p53–p21 signaling and impose G0/G1 arrest [#4]. Complete loss of Gdi2 in mice causes early embryonic lethality with widespread caspase-3–dependent cell death, establishing the gene as essential for development and cell survival [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing that GDI2 is subject to oxidative/nitrative post-translational modification under tissue stress raised the question of whether such modifications alter its trafficking function.\",\n      \"evidence\": \"Mass spectrometry of modified GDI2 peptides from a rat spinal cord injury model\",\n      \"pmids\": [\"17315910\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional consequence of the 3-aminotyrosine or acrolein modifications was tested\",\n        \"Modified residues not linked to Rab-binding or extraction activity\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying GDI2 as a direct miR-15b-5p target connected its expression level to tumor cell invasion, but left the downstream effector route unresolved.\",\n      \"evidence\": \"Dual-luciferase reporter assay with miRNA over/under-expression and GDI2 rescue in thyroid carcinoma cells\",\n      \"pmids\": [\"32945458\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Biochemical link from GDI2 to MMP2/MMP9 not established\",\n        \"No connection to the Rab-extraction mechanism\",\n        \"Single lab, single cancer context\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"GDI2 knockdown phenotypes in prostate cancer associated the protein with proliferation and apoptosis control via p75NTR, framing it as a candidate cancer dependency.\",\n      \"evidence\": \"shRNA knockdown with proliferation/apoptosis assays and p75NTR/NF-κB readouts plus xenograft\",\n      \"pmids\": [\"34051575\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Mechanistic link between GDI2 and p75NTR not biochemically established\",\n        \"Single method per endpoint\",\n        \"No connection to Rab cycling demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining the consequence of total GDI2 loss in vivo answered whether the gene is essential, showing it is required for embryonic survival.\",\n      \"evidence\": \"Gdi2 null mouse with histology, TUNEL, and cleaved caspase-3 staining\",\n      \"pmids\": [\"35689892\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Which Rab-dependent trafficking step underlies the lethality is not defined\",\n        \"Cell-type origin of the apoptotic phenotype not pinpointed\",\n        \"No rescue experiment\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Pinpointing a direct GDI2–Rab1A interaction and a druggable Tyr245 site mechanistically tied GDI2 to ER-to-Golgi transport and to ER-stress-driven cell death.\",\n      \"evidence\": \"Activity-based protein profiling, NanoLuc screening, Co-IP/pulldown, BQZ-485 pharmacology and xenograft\",\n      \"pmids\": [\"37885576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Rab1A is the sole client mediating the paraptotic phenotype is unresolved\",\n        \"Structural basis of the Tyr245-dependent interaction not solved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying itaconate alkylation at Cys203/335/414 defined a physiological switch that inhibits GDI2-mediated Rab extraction, linking metabolite signaling to membrane Rab retention and viral infection.\",\n      \"evidence\": \"Activity-based alkylation assay, cysteine-mutant validation, GGTase-II dependence, in vivo and single-cell RNA-seq\",\n      \"pmids\": [\"39730330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which specific Rab clients are most affected by alkylation in vivo not fully enumerated\",\n        \"Quantitative impact on distinct trafficking routes not resolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connecting GDI2 to APP routing and to RAB5A/p53 signaling extended its trafficking role into disease-relevant outputs (Aβ production and cell-cycle control).\",\n      \"evidence\": \"Neuron-specific Gdi2 KO in 5xFAD mice with APP co-localization and Aβ assays; reciprocal Co-IP of GDI2-RAB5A with epistasis rescue in colorectal cancer cells\",\n      \"pmids\": [\"38382624\", \"39323841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether APP rerouting is a direct Rab effect or indirect not dissected\",\n        \"How GDI2 loss increases free RAB5A to activate p53 mechanistically unresolved\",\n        \"Cross-tissue generality not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The full spectrum of GDI2 Rab clients and how client selectivity dictates distinct trafficking and disease outcomes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No comprehensive map of GDI2-extracted Rabs across cell types\",\n        \"Structural model of GDI2-Rab membrane extraction not established in this corpus\",\n        \"Causal Mendelian disease link absent from the corpus\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RAB1A\", \"RAB5A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}